Slide 1: Investor Presentation Q2FY20
Investor Presentation Q2FY20 06-11-2019
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Key highlights
Key highlights: Overall India Rx India Gx South Africa 1 Continued growth across key markets 10% 13% 61% 13% (Q2 YoY Growth) (Q2 YoY Growth) (QoQ Growth) (Private Market Q2 YoY Growth; ZAR ) 2 Strong EBITDA margin ~21% 21% trajectory (Q2 EBITDA) Q2 EBITDA YoY Growth Retained share in Cinacalcet 3 Mo
Slide 4: Financial Performance – Q2FY20
Financial Performance – Q2FY20 Revenues INR 4,396 Cr 10% EBITDA INR 909 Cr ~21% to sales 21% Q2 FY20 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q2 FY 19 (Rs Cr) 4% 4% Total Revenue from Europe, 4% 4,396 10% Operations a) Domestic Sales 1,810 9% Emerging India, 40% Mkts, 10% b) I
Slide 5: Continued focus on maintaining balance sheet health with strong cash flow generation
Continued focus on maintaining balance sheet health with strong cash flow generation Gross Debt Net Debt / Equity 4,316 0.10 3,557 0.08 Mar'19 Sept'19 Mar'19 Sept'19 Loan repayment of US$110mn made during the quarter, a year ahead of schedule Reduction in Net Debt/Equity despite continued growth
Slide 6: India (Rx + Gx): Strong recovery in generics and momentum in branded business
India (Rx + Gx) : Strong recovery in the generics business and momentum across key therapies in the branded business Q2 Y-o-Y Q2 Q-o-Q Rs Cr Rs Cr 2000 2000 1745 1745 1800 1800 1644 29% 6% 1600 1355 1600 1400 1400 1200 1200 1000 1000 800 800 600 600 400 400 200 200 0 0 Q2 FY 19 Q2 FY 20 Q1 FY20 Q2 F
Slide 7: North America: Momentum continues behind new launches and retained share
North America: Momentum continues behind new launches and retained share on key assets Key Business Highlights Q1 Y-o-Y • Continue to retain share in Cinacalcet despite multiple competitors launching the product; contribution in value terms substantially normalized $ Mn • Launch of Pregabalin and Da
Slide 8: ANDA Portfolio & Pipeline (As on 30th Sept 2019)
ANDA1 Portfolio & Pipeline (As on 30th Sept 2019) Total 172 22 63 257 ANDAs ANDA Portfolio 31 56 9 4 23 76 2 3 1 34 11 7 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd Cipla-PEPFAR2 Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR approved ANDAs can be
Slide 9: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q2 Y-o-Y Q2 Q-o-Q $ Mn $ Mn SA Private Market 13% YoY 36 28 23 28 ZAR Terms 21 30 21 20 9% 18% South Africa Private South Africa 52 56 48 56 Tender Others (SSA & CGA) Q2 FY19 Q2 FY20 Q1 FY20 Q2 FY20 Key Business Highlights South Africa:
Slide 10: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 30 30 80 27 24 67 25 33% 25 22 70 64 -9% -5% 20 60 20 20 50 15 15 40 30 10 10 20 5 5 10 0 0 0 Q2 FY19 Q2 FY20 Q2 FY19 Q2 FY20 Q2 FY19 Q2 FY20 Strengthening portfolio offering in key markets: Growth driven by performance in key Key cus
Slide 11: Key priorities for the upcoming quarters
Key priorities for the upcoming quarters: India Leverage on the momentum and continue to drive performance across both branded and 1 o generics o Launch Berok 2.0: Second version of Cipla’s flagship patient-focused initiatives in Respiratory South Africa 2 o Continue growth momentum in the private m
Slide 12: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q2FY20 12